创仑供应进口Cellabs热带病快检试剂盒
广州健仑生物科技有限公司
广州健仑长期供应各种生物原料,主要代理品Pai:美国Seracare、西班牙Certest、美国Fuller、美国NOVABIOS、 Cellabs等等。
Cellabs公司是一个ling先的生物技术公司,总部位于澳大利亚悉尼。专门研发与生产针对热带传染性疾病的免疫诊断试剂盒。其产品畅销40多个国家和地区。1998年,Cellabs收购TropBio公司,进一步巩固其在研制热带传染病、寄生虫诊断试剂方面的ling先位置。
创仑供应进口Cellabs热带病快检试剂盒
该公司的Crypto/Giardia Cel IFA是国标*推荐的两虫检测IFA染色试剂、Crypto Cel Antibody Reagent是UK DWI水质安全评估检测的抗体。
主要产品包括:隐孢子虫诊断试剂,贾第虫诊断试剂,疟疾诊断试剂,衣原体检测试剂,丝虫诊断试剂,锥虫诊断试剂等。
广州健仑生物科技有限公司与cellabs达成代理协议,欢迎广大用户咨询订购。
我司还提供其它进口或国产试剂盒:登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
欢迎咨询
欢迎咨询2042552662
【Seracare产品介绍】
货号 | 产品名称 | 产品描述 | 规格 |
免疫荧光试剂盒(IFA kit) |
KR1 | Crypto Cel | 隐孢子虫(Cryptosporidium)间接免疫荧光检测试剂 | 50 Test |
KR2 | Crypto/Giardia Cel | 隐孢子虫&贾第虫(Cryptosporidium & Giardia)间接免疫荧光检测试剂 | 50 Test |
KG1 | Giardia Cel | 贾第虫(Giardia)间接免疫荧光检测试剂 | 50 Test |
KC1 | Chlamydia Cel | 沙眼衣原体(Chlamydia trachomatis)间接免疫荧光检测试剂 | 50 Test |
KC2 | Chlamydia Cel LPS | 衣原体 lipopolysaccharide (LPS)间接免疫荧光检测试剂 | 50 Test |
KC3 | Chlamydia Cel Pn | 肺炎衣原体(Chlamydia pneumoniae)间接免疫荧光检测试剂 | 50 Test |
KP1 | Pneumo Cel | 卡氏肺孢子虫(Pneumocystis carinii)间接免疫荧光检测试剂 | 50 Test |
KP2 | Pneumo Cel Indirect | 卡氏肺孢子虫( Pneumocystis carinii)间接免疫荧光检测试剂 | 50 Test |
酶免试剂盒 ELISA kit |
KG2 | Giardia CELISA | 贾第虫(Giardia)ELISA kit | 96 Test |
KE1 | Entamoeba CELISA Path | 溶组织内阿米巴(Entamoeba histolytica) ELISA kit | 96 Test |
KF1 & KF2 | Filariasis CELISA | 班氏丝虫(Wuchereria bancrofti ) ELISA kit | |
KM2 | Malaria Antigen (HRP2) CELISA | 恶性疟原虫(Plasmodium falciparum) 抗原 ELISA kit | 192 Test |
KMC3 | Pan Malaria Antibody CELISA | 间日、三日、恶性及卵形疟疾(Malaria)ELISA IgG kit | 192 Test |
KT2 | T. cruzi IgG CELISA | 克氏锥虫(Trypanosoma cruzi) ELISA IgG kit | 192 Test |
KT3 | Toxocara IgG CELISA | 弓首线虫(Toxocara canis) ELISA IgG kit | 192 Test |
KF3 | Filariasis Ab (Bm14) CELISA | 淋巴丝虫病(lymphatic filariasis) ELISA IgG kit | 480 Test |
KM7 | Quantimal™ pLDH Malaria CELISA | 疟疾pLDH抗体检测 ELISA kit | 96 Test |
Severity
One-sixth of the population, that is, one billion people, is infected with one or more diseases. These diseases are not valued in the national health plan. These diseases are mainly concentrated in low-income countries in Africa and Latin America, where as many as five to seven diseases may be simultaneously prevalent in large areas of these countries. These diseases have also paid a heavy price in parts of Asia and the Middle East, but the number of overlaps is relatively small.
example
Since writing records, most of these diseases have caused catastrophes to humanity. Since the Biblical era, historical records have been full of descriptions of the pain, disability, and stigma caused by diseases such as leprosy. Some other diseases such as African sleeping sickness are notorious and have caused extremely serious clinical consequences. After the patient's brain was attacked by parasites, if the diagnosis and treatment were not timely, the mortality rate was . Some diseases are not as well known, but they also have the same serious consequences. Onchocerciasis and trachoma can cause blindness. Buruli ulcers and some forms of leishmaniasis destroy soft tissues and can attack bones. Chagas disease and other forms of leishmaniasis severely damage the internal organs. Guinea worm disease caused severe pain that kept the patient bedridden for months. Lymphatic filariasis causes disability and severe swelling of the limbs and external organs of patients. Schistosomiasis and soil-borne helminths cause severe anaemia, resulting in malnutrition, affecting child development and growth.
Why are they neglected
The disease is not very eye-catching. They do not cause a large-scale outbreak and have not caught the attention of the public and the press. They have not spread internationally. Despite the enormous and long-term suffering, they did not result in the loss of a large number of people and did not affect rich countries. When developing a health agenda and budget, these diseases are often overlooked. The funds available for health investment in endemic countries are limited. These diseases must compete with more dramatic diseases that have a much higher mortality rate and cause great concern at home and abroad. Most of the pain caused by neglected tropical diseases is unknown. Patients are concentrated in remote rural areas and in the huge slums of suburban areas, without access to safe drinking water, low levels of education, poor sanitation, poor housing, and possibly no access to health care. There are other reasons why these diseases are unknown. Patients have difficulty accessing medical services, and poor families cannot afford expensive expenses. As a result, many people have been dragged to the point where they are severe enough to be unable to reverse their illness. The stigma associated with crippled and disfigured diseases makes patients, especially female patients, unwilling to seek medical attention. In the research and development field, these diseases are also ignored. There is insufficient incentive to develop new diagnostic tools, drugs, and vaccines for diseases that have a market, but patients are unable to pay for medical expenses.
Common disease
In addition to the terrestrial helminth disease affecting more than one billion people, the six most neglected tropical diseases are:
Schistosomiasis
The number of people infected is more than 200 million. About 120 million people have symptoms and about 20 million people are in serious condition.
Lymphatic filariasis
The number of infected people is about 120 million people. The disease is the second most common cause of death in the world.
Blinding trachoma
The number of infected people is about 80 million people, of whom 6 million are blind. The disease is the leading cause of blindness in the world.
Onchocerciasis
The number of infected people is about 37 million people, and the vast majority of patients are in Africa. The disease causes severe dermatitis, visual impairment or blindness, and the patient's life expectancy may be shortened by up to 15 years.
Chagas disease
The number of infected people is about 13 million, mostly concentrated in Latin America. Due to factors such as immigration, blood transfusions, congenital transmission, and organ donation, the disease has emerged in areas previously considered to be free of the disease as well as in non-endemic countries, so control and supervision work is very much needed.
Leishmaniasis
More than 12 million people are infected in 88 countries in Africa, Asia, Europe and the Americas. According to WHO estimates, 350 million people are under threat and the number of new infections each year reaches 1.5 million to 2 million. The rapidly fatal visceral leishmaniasis is the most serious form of the disease and is creating a worrying global trend.
二维码扫一扫
【公司名称】 广州健仑生物科技有限公司
【】 杨永汉
【】
【腾讯 】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室
【企业文化】